Compatibility and activity of aldesleukin (recombinant interleukin-2) in presence of selected drugs during simulated Y-site administration: evaluation of three methods.
The compatibility and biological activity of aldesleukin (a form of recombinant interleukin-2) in the presence of selected i.v. drugs during simulated Y-site administration was studied. Five milliliters of aldesleukin 33,800 IU/mL in 5% dextrose injection was mixed in glass test tubes with 5 mL of each of 19 i.v. drugs prepared at concentrations used in routine clinical practice. The compatibility of the combinations was assessed by visual examination and spectrophotometry at 0, 0.5, 1, and 2 hours after preparation, and bioassays were conducted to determine the activity of aldesleukin in the combinations. Lorazepam was the only drug visually incompatible with aldesleukin. All the secondary drugs were spectrophotometrically compatible with aldesleukin. However, the bioassays showed that the following drugs reduced the activity of aldesleukin: ganciclovir sodium, lorazepam, pentamidine isethionate, prochlorperazine edisylate, and promethazine hydrochloride. Thus, aldesleukin became less biologically active when combined with four drugs for which visual examination suggested compatibility and when combined with five drugs for which spectrophotometry indicated compatibility. Aldesleukin 33,800 IU/mL in 5% dextrose injection lost significant biological activity in the presence of prochlorperazine edisylate, promethazine hydrochloride, lorazepam, ganciclovir sodium, and pentamidine isethionate during simulated Y-site administration. Visual assessment and spectrophotometry may not be valid methods for assessing possible changes in the biological activity of aldesleukin when combined with other agents.
Alex
S
S
Asco Health Care, Inc., Columbia, MD, USA.
Gupta
S L
SL
Minor
J R
JR
Turcovski-Corrales
S
S
Gallelli
J F
JF
Taub
D
D
Piscitelli
S C
SC
D000890:Anti-Infective Agents / Q000737:chemistry; D000925:Anticoagulants / Q000737:chemistry; D000932:Antiemetics / Q000737:chemistry; D001681:Biological Assay; D004298:Dopamine / Q000737:chemistry; D004344:Drug Incompatibility; D004355:Drug Stability; D004359:Drug Therapy, Combination; D004573:Electrolytes / Q000737:chemistry; D005947:Glucose / Q000737:chemistry; D006635:Histamine H2 Antagonists / Q000737:chemistry; D007275:Injections, Intravenous / Q000379:methods*; D007376:Interleukin-2 / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000737:chemistry; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000737:chemistry; D013053:Spectrophotometry; D013997:Time Factors
D000890:Anti-Infective Agents; D000925:Anticoagulants; D000932:Antiemetics; D004573:Electrolytes; D006635:Histamine H2 Antagonists; D007376:Interleukin-2; D011994:Recombinant Proteins; D005947:Glucose; C082598:aldesleukin; D004298:Dopamine